Evidence map›Paper›PMID 31139366›Full record

ArticleAntimicrobial resistance and infection control2019

Technology for the prevention of antimicrobial resistance and healthcare-associated infections; 2017 Geneva IPC-Think Tank (Part 2).

Walter Zingg, Benjamin J Park, Julie Storr, Raheelah Ahmad, Carolyn Tarrant, Enrique Castro-Sanchez, Eli Perencevich, Andreas Widmer, Karl-Heinz Krause, Claire Kilpatrick and 5 more

Abstract read
In one paragraph

Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Walter ZinggInfection control programme and WHO collaborating center, University of Geneva Hospitals and Faculty of Medicine, 4 Rue Gabrielle Perret-Gentil, 1211, Geneva 14, Switzerland.
Benjamin J Park2US Centers for Disease Control and Prevention, Atlanta, GA USA.
Julie Storr3Infection Prevention and Control Global Unit, World Health Organization, Geneva, Switzerland.
Raheelah Ahmad4National Institute for Health Research in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, UK.
Carolyn Tarrant5Department of Health Sciences, University of Leicester, Leicester, UK.
Enrique Castro-Sanchez4National Institute for Health Research in Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, UK.
Eli Perencevich6Carver College of Medicine, University of Iowa, Iowa City, USA.
Andreas Widmer7Infection Control Programme, University Hospitals of Basel, Basel, Switzerland.
Karl-Heinz Krause8Institute of Genetics and Genomics, University of Geneva, Geneva, Switzerland.
Claire Kilpatrick3Infection Prevention and Control Global Unit, World Health Organization, Geneva, Switzerland.
Sara Tomczyk3Infection Prevention and Control Global Unit, World Health Organization, Geneva, Switzerland.
Benedetta Allegranzi3Infection Prevention and Control Global Unit, World Health Organization, Geneva, Switzerland.
Denise Cardo2US Centers for Disease Control and Prevention, Atlanta, GA USA.
Didier PittetInfection control programme and WHO collaborating center, University of Geneva Hospitals and Faculty of Medicine, 4 Rue Gabrielle Perret-Gentil, 1211, Geneva 14, Switzerland.
2017 Geneva IPC-Think Tank

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The high burden of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) is partially due to excessive antimicrobial use both in human and animal medicine worldwide. How can technology help to overcome challenges in infection prevention and control (IPC) and to prevent HAI and emerging AMR? Methods: In June 2017, 42 international experts convened in Geneva, Switzerland to discuss four potential domains of technology in IPC and AMR: 1) role and potential contribution of microbiome research; 2) whole genome sequencing; 3) effectiveness and benefit of antimicrobial environmental surfaces; and 4) future research in hand hygiene. Results: Research on the microbiome could expand understanding of antimicrobial use and also the role of probiotics or even faecal transplantation for therapeutic purposes. Whole genome sequencing will provide new insights in modes of transmission of infectious diseases. Although it is a powerful tool for public health epidemiology, some challenges with interpretation and costs still need to be addressed. The effectiveness and cost-effectiveness of antimicrobially coated or treated environmental high-touch surfaces requires further research before they can be recommended for routine use. Hand hygiene implementation can be advanced, where technological enhancement of surveillance, technique and compliance are coupled with reminders for healthcare professionals. Conclusions: The four domains of technological innovation contribute to the prevention of HAI and AMR at different levels. Microbiome research may offer innovative concepts for future prevention, whole genome sequencing could detect new modes of transmission and become an additional tool for effective public health epidemiology, antimicrobial surfaces might help to decrease the environment as source of transmission but continue to raise more questions than answers, and technological innovation may have a role in improving surveillance approaches and supporting best practice in hand hygiene.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsBacteriaCross InfectionGroup ProcessesHand HygieneHealth PersonnelHumansInfection ControlInternationalityMicrobiotaSwitzerlandTechnologyWhole Genome SequencingAnti-Bacterial AgentsCDCCopperECDCHand hygieneInfection prevention and controlMicrobiomeTechnologyWHOWhole genome sequencing

Identifiers

PMID31139366
PMCPMC6530187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.